Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In 2008, the US Food and Drug Administration (FDA) issued guidance requiring robust assessment of cardiovascular safety for all antidiabetic drugs to be licensed in the future. Here, we review the circumstances giving rise to the FDA guidance and describe the characteristics of clinical trials registered on ClinicalTrials.gov in the 36 months before and after the guidance was issued. We noted a doubling in the number of cardiovascular outcome trials registered and a sixfold increase in the median number of patients included in cardiovascular outcome trials in the latter 36 months. As the size and duration of follow-up for these trials increases, the clinical trials industry will need to adapt. The present review summarizes current attempts to streamline trial design and management to meet the requirements efficiently while adhering to the highest scientific standards.

Original publication

DOI

10.1007/s11886-011-0229-7

Type

Journal article

Journal

Curr Cardiol Rep

Publication Date

02/2012

Volume

14

Pages

59 - 69

Keywords

Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Diabetic Angiopathies, Female, Guideline Adherence, Health Policy, Humans, Hypoglycemic Agents, Male, Practice Guidelines as Topic, Research Design, United States, United States Food and Drug Administration